CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.307
-0.012 (-3.84%)
At close: Apr 28, 2026
CytoDyn Employees
CytoDyn had 13 employees as of May 31, 2025. The number of employees increased by 4 or 44.44% compared to the previous year.
Employees
13
Change (1Y)
4
Growth (1Y)
44.44%
Revenue / Employee
n/a
Profits / Employee
-$3,098,154
Market Cap
419.67M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 88 |
| Northwest Biotherapeutics | 25 |
| Vaxart | 65 |
| Nuo Therapeutics | 10 |
| Cell Source | 1 |
| Vicapsys Life Sciences | 2 |
CytoDyn News
- 1 day ago - CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer - GlobeNewsWire
- 5 days ago - CytoDyn to Host Investor Webcast - GlobeNewsWire
- 6 days ago - CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 - GlobeNewsWire
- 7 days ago - CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study - GlobeNewsWire
- 8 days ago - CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 - GlobeNewsWire
- 14 days ago - CytoDyn to Present at the AACR Annual Meeting 2026 - GlobeNewsWire
- 5 weeks ago - CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer - GlobeNewsWire
- 7 weeks ago - CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab - GlobeNewsWire